Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
      HIV Integrase/*drug effects ; HIV Integrase Inhibitors/*therapeutic use ; Time-to-Treatment/*statistics & numerical data; Adult ; Brain/diagnostic imaging ; Cognition/drug effects ; Drug Resistance, Viral/drug effects ; Functional Neuroimaging/methods ; HIV Infections/drug therapy ; HIV Integrase/metabolism ; HIV Integrase Inhibitors/metabolism ; HIV-1/metabolism ; HIV-1/pathogenicity ; Humans ; Male ; Neuroimaging/methods ; Prospective Studies ; Spain ; Time Factors
    • نبذة مختصرة :
      Integrase strand transfer inhibitors (INSTI) are a main component of the current antiretroviral regimens recommended for treatment of HIV infection. However, little is known about the impact of INSTI on neurocognition and neuroimaging. We developed a prospective observational trial to evaluate the effects of INSTI-based antiretroviral therapy on comprehensive brain outcomes (cognitive, functional, and imaging) according to the time since HIV-1 acquisition. We recruited men living with HIV who initiated antiretroviral therapy with INSTI < 3 months since the estimated date of HIV-1 acquisition (n = 12) and > 6 months since estimated date of HIV-1 acquisition (n = 15). We also recruited a group of matched seronegative individuals (n = 15). Assessments were performed at baseline (before initiation of therapy in HIV arms) and at weeks 4 and 48. Baseline cognitive functioning was comparable between the arms. At week 48, we did not find cognitive differences between starting therapy with INSTI earlier than 3 months or later than 6 months after acquisition of HIV-1 infection. Functional status was poorer in individuals diagnosed earlier. This effect recovered 48 weeks after initiation of therapy. Regarding brain imaging, we found that men living with HIV initiating antiretroviral therapy later experienced a greater decrease in medial orbitofrontal cortex over time, with expected negative repercussions for decision-making tasks.
    • References:
      AIDS Behav. 2014 Jun;18(6):1124-32. (PMID: 24385231)
      Infection. 2020 Feb;48(1):37-42. (PMID: 31691905)
      J Neurovirol. 2010 Mar;16(2):101-14. (PMID: 20345318)
      J Int Neuropsychol Soc. 2004 May;10(3):317-31. (PMID: 15147590)
      Gen Hosp Psychiatry. 2003 Jul-Aug;25(4):277-83. (PMID: 12850660)
      BMC Infect Dis. 2011 Dec 28;11:356. (PMID: 22204557)
      AJNR Am J Neuroradiol. 2018 Jan;39(1):54-62. (PMID: 29097412)
      J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):393-9. (PMID: 26509933)
      Clin Infect Dis. 2018 Nov 13;67(11):1697-1704. (PMID: 29697762)
      Neurology. 2010 Dec 7;75(23):2087-96. (PMID: 21135382)
      PLoS Pathog. 2017 Jan 3;13(1):e1006112. (PMID: 28046096)
      Neurology. 2014 Oct 28;83(18):1592-600. (PMID: 25261502)
      Brain Imaging Behav. 2016 Sep;10(3):640-51. (PMID: 26303224)
      Cereb Cortex. 2012 Sep;22(9):2065-75. (PMID: 22016479)
      PLoS One. 2017 Aug 30;12(8):e0182547. (PMID: 28854283)
      Neurology. 2016 Jan 26;86(4):334-40. (PMID: 26718568)
      JAMA. 2018 Jul 24;320(4):379-396. (PMID: 30043070)
      J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):563-570. (PMID: 28129254)
      Annu Rev Neurosci. 2007;30:31-56. (PMID: 17417936)
      Front Neurosci. 2013 Feb 05;6:197. (PMID: 23386806)
      Neurology. 2007 Oct 30;69(18):1789-99. (PMID: 17914061)
      Brain Imaging Behav. 2011 Jun;5(2):77-85. (PMID: 21264551)
      Neurology. 2013 Jan 22;80(4):371-9. (PMID: 23303852)
      Acta Psychiatr Scand. 1983 Jun;67(6):361-70. (PMID: 6880820)
      J Neurovirol. 2011 Feb;17(1):50-7. (PMID: 21165782)
      Med Care. 1991 Aug;29(8):786-98. (PMID: 1875745)
      Span J Psychol. 2006 May;9(1):86-93. (PMID: 16673626)
      PLoS One. 2012;7(11):e49272. (PMID: 23229129)
      J Infect Dis. 2019 Nov 6;220(12):1885-1891. (PMID: 30668739)
      AIDS Behav. 2017 Nov;21(11):3238-3246. (PMID: 28484888)
      Lancet. 2004 Jan 31;363(9406):392-4. (PMID: 15074306)
      Neuroimage. 2007 Oct 15;38(1):95-113. (PMID: 17761438)
      Curr HIV/AIDS Rep. 2013 Sep;10(3):235-43. (PMID: 23860944)
      J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):374-383. (PMID: 27454251)
      Cells. 2019 Sep 28;8(10):. (PMID: 31569373)
      AIDS. 2019 Jul 15;33(9):1477-1483. (PMID: 31008801)
      JAMA Neurol. 2018 Jan 1;75(1):72-79. (PMID: 29131878)
      Neuroimage. 2005 Jul 1;26(3):839-51. (PMID: 15955494)
      AIDS Rev. 2019;21(1):4-10. (PMID: 30899113)
      Front Pharmacol. 2021 Jan 28;11:617149. (PMID: 33584297)
    • الرقم المعرف:
      0 (HIV Integrase Inhibitors)
      EC 2.7.7.- (HIV Integrase)
      YY6481J2FF (p31 integrase protein, Human immunodeficiency virus 1)
    • الموضوع:
      Date Created: 20210529 Date Completed: 20211119 Latest Revision: 20211119
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC8163778
    • الرقم المعرف:
      10.1038/s41598-021-90678-6
    • الرقم المعرف:
      34050221